This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A third look at Alnylam's vutrisiran and the positive topline results from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Ticker(s): ALNY

Who's the expert?

Instituion: Bassett Medical Center

  • Medical director of the cardiac catheterization laboratory and director of the interventional and structural heart program
  • Extensive experience in Interventional Cardiac Procedures and Heart Conditions.
  • Specializes in interventional cardiology, structural heart diseases, nuclear cardiology, peripheral endovascular interventions and non-invasive cardiology.

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.